恆指跌近400點 醫藥股普遍捱沽 威高股份(01066.HK)及中國中藥(00570.HK)齊挫14%
恆指午後跌幅進一步擴至390點或近2.4%,現報16,144,總成交額597億元。
醫藥股今天普遍捱沽,尤其是威高股份(01066.HK)及中國中藥(00570.HK)表現最差,前者股價續挫14%報6.13元,創約五年低,成交增至1,154萬股;後者扭三連升,股價一舉失守4條主要移動平均線(100天及250天分別爲3.76及3.55元),最低見3.27元,現報3.31元,急挫14%,成交急增至9,391萬股。
藥明合聯(02268.HK)失守20天線(30.85元),最低見27.95元,現報29.05元,續跌6.3%。藍籌藥明生物(02269.HK)五連跌兼創逾三年低,最低見25.85元,現報25.9元,續挫6%。綠葉製藥(02186.HK)失守百天線(3.5元)後,現報3.34元,續挫6.2%。
金斯瑞生物(01548.HK)、藍籌石藥(01093.HK)、翰森(03692.HK)、泰格(03347.HK)、三葉草生物(02197.HK)、騰盛博藥-B(02137.HK)及榮昌生物(09995.HK)跌約3%-4%。此外,鷹瞳科技-B(02251.HK)跌5.5%報10.4元。然而,北海康成-B(01228.HK)乾升近16%報0.89元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.